Chronic pain

Chronic pain is defined as pain enduring or recurring for a duration exceeding three months. It is often characterized by sensations such as burning, electrical impulses, throbbing, or nausea. This condition is distinguished from acute pain, which typically arises from a specific etiology, resolves upon treatment of its underlying cause, and diminishes over time. Chronic pain may persist for several years and frequently lacks any discernible physiological benefit.

Prevalent manifestations of chronic pain encompass back pain, severe headache, migraine, and facial pain. Chronic pain can precipitate profound psychological and physiological sequelae, potentially enduring throughout an individual's lifespan. Somatic complications may involve neuronal damage within the brain, specifically grey matter atrophy, insomnia and inadequate sleep, metabolic dysregulation, chronic stress, obesity, and myocardial infarction. Psychological ramifications can comprise depressive states and neurocognitive impairments.

A diverse array of therapeutic modalities is employed for the management of chronic pain. Pharmacological interventions, encompassing both opioid and non-opioid agents, alongside cognitive behavioral therapy and physical therapy, represent the predominant treatment strategies. For mild pain, medications like aspirin and ibuprofen are utilized, while more severe pain necessitates the prescription of agents such as morphine and codeine. Non-pharmacological interventions, including behavioral therapy and physiotherapy, are frequently integrated as adjunctive strategies, given their constrained efficacy when administered in isolation. Presently, no definitive cure for chronic pain exists; consequently, ongoing research explores novel management and therapeutic avenues, including nerve blocks and radiation therapy.

Globally, an average of 8% to 11.2% of individuals report experiencing severe chronic pain, with a notably higher incidence observed in industrialized nations. Epidemiological investigations indicate a prevalence ranging from 8% to 55.2% across various countries, exemplified by rates of 30-40% in the United States and 10-20% in Iran and Canada. The burden of chronic pain surpasses that of diabetes, cancer, and cardiovascular disease. Estimates from the American Medical Association indicate that chronic pain-related expenditures in the United States approximate US$560-635 billion.

Classification

In medical classification systems

ICD-11

Within the ICD-11 framework, chronic pain is categorized under the code MG30. This classification defines it as pain enduring or recurring for a period exceeding three months. Its etiology is often multifactorial, encompassing biological, psychological, and social determinants.

Subcategories of MG30 are:

• primary (MG 30.0)
• cancer-related
• postsurgical or post-traumatic
• secondary musculoskeletal
• secondary visceral
• neuropathic
• secondary headache or orofacial
• Other specified
• Unspecified

Primary chronic pain (MG30.0) has subcategories:

• widespread (characterized by diffuse pain affecting a minimum of four out of five body regions, often accompanied by emotional distress or functional impairment; this subcategory encompasses fibromyalgia)
• primary musculoskeletal
• primary headache or orofacial
• Complex regional pain syndrome
• Painful bruising syndrome
• Other specified
• Unspecified

Particular pain syndromes may be assigned to these classifications.

DSM-5

As per the DSM-5 index, a complication is designated as chronic if the resultant condition (e.g., pain, disorder, or illness) persists for a duration exceeding six months. Notably, this classification does not impose prerequisites such as physical or mental injury.

IASP

The International Association for the Study of Pain (IASP) defines pain as chronic when it endures for months or even years, extending beyond the typical recovery period following an injury or illness. The IASP employs the terminology of nociceptive, neuropathic, and nociplastic pain.

Other classification approaches

Nociceptive/Neuropathic/Nociplastic

Pain is frequently categorized into three distinct types:

• Nociceptive pain originates from inflamed or damaged tissues, leading to the activation of specialized pain receptors known as nociceptors. This category can be further subdivided into superficial, deep somatic, and deep visceral pain.

• Neuropathic pain results from damage or dysfunction within components of the nervous system. Such damage may affect the peripheral, central, or somatosensory nervous systems. Peripheral neuropathic pain is frequently characterized by sensations such as burning, tingling, electrical shocks, stabbing, or 'pins and needles'.

• Nociplastic pain is defined as pain that manifests without clear evidence of actual or threatened tissue damage, or damage to the somatosensory system, that would account for the pain.

By originating body area

Chronic pain is categorized based on its origin, including neuropathic, musculoskeletal, visceral, inflammatory, or central sensitization types.

Classification: Primary or Secondary

Chronic pain syndromes are broadly classified into primary and secondary forms. Secondary pain arises as a consequence of an underlying disease.

Etiology

The etiology of chronic pain is multifactorial, encompassing both pathophysiological and environmental elements. It can manifest following central nervous system neuropathy, cerebral hemorrhage, extensive tissue damage (e.g., severe burns), inflammation, or autoimmune conditions like rheumatoid arthritis. Psychological stressors, such as those contributing to headaches, migraines, or abdominal pain (often linked to emotional, psychological, or behavioral factors), also play a role. Furthermore, mechanical pain, exemplified by arthritis resulting from tissue degeneration, is a common cause. Additionally, genetic predispositions affecting neuronal differentiation can lead to a persistently reduced pain threshold, thereby contributing to chronic pain development.

The precise pathophysiological etiology of chronic pain is not fully understood. Existing theories often struggle to elucidate why identical pathological conditions do not consistently lead to chronic pain. An individual's anatomical predisposition to proximal neural compression, particularly involving peripheral nerves, has been proposed as a potential explanation for this phenomenon. A proximal neural lesion at the dorsal root ganglion (DRG) level might initiate a self-perpetuating cycle of chronic pain by inducing postural protection of the affected area, which in turn leads to further neural compression within the same spinal region. The diagnostic challenges associated with identifying proximal neural lesions could contribute to the theoretical complexities surrounding chronic pain.

Pathophysiology

Persistent activation and transmission of pain signals trigger a physiological response aimed at pain relief, which paradoxically involves the release of prostaglandins. This prostaglandin secretion enhances local sensitivity to stimulation, contributing to the development of intractable and chronic pain. Sustained nociceptive input to the dorsal horn can induce a "wind-up" phenomenon. This process leads to neuronal hyperexcitability, reducing the threshold for pain signal transmission. Furthermore, it can result in non-nociceptive nerve fibers acquiring the ability to respond to, generate, and transmit pain signals. It is hypothesized that unmyelinated Group C nerve fibers, characterized by their slow conduction velocity, are primarily responsible for mediating this type of prolonged pain.

Such alterations in neural structure are attributable to neuroplasticity. In the context of chronic pain, continuous noxious stimulation leads to abnormal reorganization of the somatotopic map, potentially resulting in allodynia or hyperalgesia. Once established, this neuroplastic process in chronic pain is often challenging to reverse or halt. Electroencephalography (EEG) studies in individuals with chronic pain have revealed altered brain activity and synaptic plasticity, specifically an increase in relative beta wave activity and a decrease in alpha and theta wave activity.

Dysregulation of dopamine secretion within the brain may represent a shared underlying mechanism linking chronic pain, insomnia, and major depressive disorder, contributing to their associated adverse effects. Furthermore, astrocytes, microglia, and satellite glial cells exhibit impaired function in chronic pain states. Enhanced microglial activity, alterations in microglial networks, and increased production of chemokines and cytokines by microglia are implicated in the exacerbation of chronic pain. Astrocytes have also been observed to lose their capacity to modulate neuronal excitability, leading to heightened spontaneous activity of neurons within pain circuits.

Disease Associations

Several medical conditions, including diabetes, herpes zoster (shingles), phantom limb pain, hypertension, and stroke, are implicated in the development of chronic pain.

Chronic pain is frequently associated with fibromyalgia.

Prognosis and Outcomes

Complete and long-term remission is uncommon for many forms of chronic pain, which frequently proves challenging to manage therapeutically.

Chronic pain can substantially diminish an individual's quality of life, productivity, and earning potential. It can also exacerbate pre-existing health conditions and precipitate the development of new comorbidities, such as major depression, anxiety disorders, and substance use disorders.

Commonly prescribed medications for chronic pain present various risks, including adverse effects and complications. For instance, the chronic administration of opioids is linked to a reduction in life expectancy and an elevated mortality rate among patients compared to non-users. Acetaminophen, a frequently employed analgesic in chronic pain management, can induce hepatotoxicity when doses exceed four grams daily; even therapeutic dosages may cause liver damage in patients with pre-existing chronic liver disease. Long-term risks associated with opioids, another class of analgesics, encompass constipation, the development of drug tolerance and dependence, nausea, indigestion, cardiac arrhythmias (such as QT prolongation during methadone therapy), endocrine gland dysfunctions leading to amenorrhea, erectile dysfunction, gynecomastia, and fatigue. A significant public health and clinical concern since the 2010s has been opioid overdose, particularly within the context of the opioid epidemic in the United States.

As of 2011, pharmacological interventions for chronic non-cancer pain demonstrated an average pain reduction of 30%, though their efficacy varied considerably based on treatment modality, diagnosis, and patient population. Such pain reduction has the potential to substantially enhance patients' functional capacity and quality of life. Nevertheless, the overarching long-term prognosis for chronic pain typically indicates diminished function and a reduced quality of life. Furthermore, chronic pain is associated with numerous complications, elevating the risk of mortality, the development of other chronic diseases, and obesity. Concurrently, patients requiring opioids for chronic pain frequently develop drug tolerance over time, necessitating increased dosages for efficacy, which in turn escalates the risk of adverse effects and mortality.

Mental disorders possess the capacity to intensify pain signals and exacerbate symptom severity. Moreover, co-occurring psychiatric conditions, such as major depressive disorder, can considerably impede the timely diagnosis of pain disorders. Major depressive disorder and generalized anxiety disorder represent the most prevalent comorbidities observed in conjunction with chronic pain. Annually, patients presenting with both chronic pain and comorbid mental disorders receive twice the amount of medication compared to those without such co-morbidities. Research indicates that in cases where chronic pain coexists with other disorders, therapeutic interventions targeting one condition can positively influence the improvement of the other.

Individuals experiencing chronic pain face an elevated risk of suicide and suicidal ideation. Studies indicate that approximately 20% of individuals with suicidal thoughts, and between 5% and 14% of chronic pain patients, die by suicide. Among patients who attempted suicide, 53.6% succumbed to gunshot wounds, while 16.2% died from opioid overdose.

Sleep disturbances and insomnia, often resulting from medication or illness symptoms, are commonly reported among individuals with chronic pain. The management of these conditions can be challenging, primarily due to the significant potential for medication interactions, particularly when treatment is overseen by multiple healthcare providers.

Severe chronic pain is correlated with an elevated ten-year mortality risk, specifically attributable to cardiovascular and respiratory diseases. Several underlying mechanisms have been posited to explain this increased risk, including an aberrant stress response within the body's endocrine system. Furthermore, chronic stress appears to adversely impact cardiovascular health by accelerating the accumulation of plaque on arterial walls, a process known as arteriosclerosis. Nevertheless, additional research is requisite to elucidate fully the intricate relationship among severe chronic pain, stress, and cardiovascular health.

Individuals experiencing chronic pain frequently exhibit higher rates of depression. While the precise interrelationship between these comorbidities remains to be fully elucidated, a 2017 neuroplasticity study revealed that "injury sensory pathways of body pains have been shown to share the same brain regions involved in mood management." Chronic pain can also lead to reduced physical activity, often driven by a fear of exacerbating symptoms. Moreover, the intensity of pain, an individual's perceived control over it, and their resilience to pain are all subject to influence by the varying levels and forms of social support received, as well as by their socioeconomic status.

A study employing Mendelian randomization revealed causal links between chronic pain and specific psychiatric, cardiovascular, and inflammatory conditions previously considered unrelated. Findings indicated that depression exposure heightens the probability of pain reporting, but not conversely. Similarly, exposure to coronary diseases elevates the risk of developing chronic pain, and this relationship is reciprocal. A modest increase in body mass index correlates with a higher likelihood of pain experience, whereas elevated blood HDL levels decrease the probability of chronic pain. Pertaining to inflammatory conditions, asthma exposure increases the propensity for pain, and this effect is bidirectional.

Chronic pain, irrespective of its etiology, is recognized as a condition that impacts brain structure and function. Magnetic Resonance Imaging (MRI) studies have demonstrated atypical anatomical and functional connectivity, even in resting states, within brain regions associated with pain processing. Furthermore, sustained pain has been observed to induce grey matter atrophy, a change that is reversible upon pain resolution.

The biopsychosocial model offers a framework for predicting an individual's chronic pain experience, positing that it is influenced by an intricate interplay of biological, psychological, and social environmental factors.

Chronic pain can represent a significant contributing factor to suicide.

Management

Overview

Pain management constitutes a medical specialty characterized by an interdisciplinary methodology. It integrates expertise from diverse medical and allied health professions to alleviate pain and enhance the quality of life for individuals experiencing it. A standard pain management team typically comprises medical practitioners (especially anesthesiologists), rehabilitation psychologists, physiotherapists, occupational therapists, physician assistants, and nurse practitioners. While acute pain often resolves under the care of a single practitioner, chronic pain management frequently necessitates the collaborative efforts of a multidisciplinary treatment team.

A multimodal treatment strategy is crucial for optimizing pain control and patient outcomes, concurrently minimizing reliance on high-risk interventions like opioid medications. Addressing co-occurring depression and anxiety is paramount in mitigating chronic pain. Patients afflicted with chronic pain require vigilant monitoring for severe depression, suicidal ideation, and planning. Regular referrals for physical examinations and treatment efficacy assessments are also essential. Prompt and appropriate management of chronic pain can avert potential adverse impacts on a patient's life and mitigate escalating healthcare expenditures.

As of 2024, patients are encouraged to assume a significant role in their pain management.

Medications

Initial recommendations for chronic pain treatment often involve various non-opioid medications, with selection contingent upon whether the pain originates from tissue damage or is neuropathic.

While some individuals with chronic pain may derive benefit from opioid therapy, others may experience adverse effects.

For individuals experiencing non-cancer pain unresponsive to non-opioid medications, opioid trials may be considered, provided there is no history of substance use disorder or current mental illness.

Non-opioids

Initial therapeutic approaches primarily involve non-opioid-based interventions. Pharmacological non-opioid treatments for chronic pain may encompass acetaminophen (paracetamol) or nonsteroidal anti-inflammatory drugs (NSAIDs).

A range of other non-opioid medications can be employed, with selection guided by whether the pain stems from tissue damage or is neuropathic (i.e., pain resulting from a damaged or dysfunctional nervous system).

Evidence is limited regarding the superior efficacy of opioids for treating cancer pain or chronic pain arising from tissue damage due to conditions such as rheumatoid arthritis.

In cases of neuropathic pain, certain medications, including tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and anticonvulsants, may demonstrate greater efficacy than opioids.

Certain atypical antipsychotics, such as olanzapine, may also prove effective, though supporting evidence remains preliminary. For women experiencing chronic pain, hormonal medications like oral contraceptive pills might offer relief. In situations where no single optimal treatment is clearly indicated, clinicians may need to identify personalized therapies that are effective for the individual patient.

Nefopam can be employed when conventional alternatives are contraindicated, prove ineffective, or as an adjunctive treatment. Nevertheless, its use is linked to adverse drug reactions and toxicity in cases of overdose.

Opioids

For individuals who have not responded to other interventions and lack a history of mental illness or substance use disorder, opioid treatment may be considered. However, if substantial benefit is not observed, discontinuation is advised. Among patients currently receiving opioids, reducing or ceasing their use can lead to improved outcomes, including pain reduction.

While some individuals with chronic pain derive benefit from opioid therapy, others do not, and some may experience harm. Potential adverse effects encompass diminished sex hormone production, hypogonadism, infertility, compromised immune function, increased risk of falls and fractures in older adults, neonatal abstinence syndrome, cardiac issues, sleep-disordered breathing, physical dependence, addiction, abuse, and overdose.

Clinicians face challenges in predicting which patients will utilize opioids solely for pain management versus those who will develop an addiction. Furthermore, discerning whether patients request opioids due to an existing opioid addiction presents another difficulty. Conversely, withholding, interrupting, or discontinuing opioid treatment in individuals who benefit from it can result in adverse consequences.

Psychological Treatments

Psychological interventions, such as cognitive behavioral therapy and acceptance and commitment therapy, can contribute to enhancing quality of life and mitigating pain interference. While brief mindfulness-based treatment approaches have been employed, they are not currently endorsed as primary treatments. Nevertheless, the efficacy of mindfulness-based pain management (MBPM) has been substantiated by various research studies.

In older adult populations, psychological interventions can aid in pain reduction and foster improved self-efficacy for pain management. Additionally, psychological treatments have demonstrated effectiveness in pediatric and adolescent patients experiencing chronic headaches or various chronic pain conditions.

Exercise

Although exercise has been proposed as a strategy to alleviate chronic pain, and some evidence suggests benefit, this evidence remains preliminary. For individuals experiencing chronic pain, exercise typically presents minimal side effects.

Other Interventions

Interventional pain management may be considered, encompassing techniques like trigger point injections, neurolytic blocks, and radiotherapy. Although high-quality evidence for ultrasound is lacking, it has been observed to exert a modest effect on functional improvement in non-specific chronic low back pain.

Alternative Medicine

Alternative medicine encompasses health practices or products employed for pain or illness treatment that are not inherently integrated into conventional medical approaches. In the context of chronic pain, these practices are typically categorized into four main types: biological, mind-body, manipulative body, and energy medicine.

The implementation of dietary modifications, classified as a biological-based alternative medicine practice, has demonstrated potential in ameliorating chronic pain symptoms over time. Incorporating supplements into the diet represents a frequent dietary adjustment aimed at chronic pain relief. Among the most extensively researched supplements are acetyl-L-carnitine, alpha-lipoic acid, and vitamin E. Vitamin E, notably, is arguably the most studied of these three, with robust evidence indicating its role in reducing neurotoxicity in individuals with cancer, multiple sclerosis, and cardiovascular diseases.

Hypnosis, including self-hypnosis, is supported by tentative evidence. Specifically, hypnosis can provide pain relief for a majority of individuals and may serve as a safe alternative to pharmaceutical interventions. However, evidence does not substantiate the use of hypnosis for chronic pain resulting from a spinal cord injury.

Preliminary investigations suggest that medical marijuana may be beneficial for treating neuropathic pain, though not other forms of long-term pain. As of 2018, the evidence supporting its efficacy for neuropathic pain or pain linked to rheumatic diseases is not robust, necessitating further research. Regarding chronic non-cancer pain, a recent study concluded that cannabinoids are unlikely to be highly effective. Nevertheless, more rigorous research on cannabis or cannabis-based medicines is warranted.

Tai chi has demonstrated efficacy in ameliorating pain, stiffness, and overall quality of life for individuals suffering from chronic conditions like osteoarthritis, low back pain, and osteoporosis. Similarly, acupuncture has been identified as a safe and effective therapeutic option for mitigating pain and enhancing the quality of life in various chronic pain syndromes, including chronic pelvic pain.

High-quality evidence does not substantiate the use of transcranial magnetic stimulation for chronic pain reduction, as its observed effects are minimal and transient.

While spa therapy may offer potential benefits for alleviating chronic lower back pain, further research is requisite to establish more robust empirical support.

Investigations into the efficacy of St. John's Wort or nutmeg for managing neuropathic pain have yielded findings that provoke substantial concerns regarding the precision of their reported outcomes.

Kinesio tape has not demonstrated effectiveness in the management of chronic non-specific low-back pain.

Although myofascial release has been applied in certain instances of fibromyalgia, chronic low back pain, and tennis elbow, insufficient evidence exists to endorse its widespread adoption as a therapeutic modality.

Epidemiology

Chronic pain is a prevalent health concern.

• Epidemiological investigations indicate that chronic widespread pain affects 8–11.2% of individuals across diverse nations. The prevalence of chronic pain globally ranges significantly, impacting between 8% and 55% of the population. This condition disproportionately affects women and constitutes a substantial burden on healthcare resources worldwide.
• A comprehensive telephone survey encompassing 15 European countries and Israel revealed that 19% of respondents aged 18 and older had experienced pain for over six months, including the preceding month, with occurrences more than twice in the last week, and a pain intensity of 5 or higher on a 1-10 scale (where 1 signifies no pain and 10 represents the worst imaginable). Among the 4,839 chronic pain sufferers interviewed in detail, 66% reported moderate pain intensity (5–7), while 34% reported severe pain (8–10). Furthermore, 46% experienced constant pain, 56% intermittent pain, and 49% had endured pain for 2–15 years. Notably, 21% had received a diagnosis of depression attributed to their pain. The impact on employment was significant, with 61% reporting reduced or complete inability to work outside the home, 19% having lost employment, and 13% having changed jobs due to their condition. The survey also highlighted deficiencies in care, as 40% received inadequate pain management, and fewer than 2% consulted a pain management specialist.
• In the United States, chronic pain is estimated to affect approximately 35% of the population, resulting in partial or total disability for about 50 million Americans. The Institute of Medicine reports that approximately 116 million Americans live with chronic pain, suggesting that nearly half of all American adults contend with some form of chronic pain condition. A more conservative estimate from the Mayday Fund places this figure at 70 million Americans. An internet-based study determined the prevalence of chronic pain in the United States to be 30.7% of the population, specifically 34.3% among women and 26.7% among men. A 2021 survey further indicated that 55% of chronic pain sufferers were female.
• In Canada, approximately one in five Canadians are estimated to experience chronic pain, with half of these individuals having endured the condition for a decade or more. The prevalence and severity of chronic pain in Canada are notably higher among women and within Indigenous communities.
• In the United Kingdom, chronic pain impacts 13–50% of the adult population. Among those affected, 10.4–14.3% experience moderate-to-severe disabling chronic pain.

Psychological Aspects

Personality

The Minnesota Multiphasic Personality Inventory (MMPI) frequently identifies two distinct personality profiles among individuals with chronic pain: the conversion V and the neurotic triad. The conversion V profile is characterized by an amplified preoccupation with somatic sensations, the manifestation of physical symptoms in response to stress, and a frequent inability to acknowledge one's own emotional states, including depression. Conversely, the neurotic triad profile also exhibits heightened concern regarding bodily sensations and develops physical symptoms under stress, but is further distinguished by demanding and complaining behaviors.

Initial hypotheses suggested neuroticism as a precursor to chronic pain; however, clinical data indicate the reverse, positing that chronic pain induces neuroticism. Following successful therapeutic interventions that alleviate persistent pain, individuals often exhibit a reduction in neurotic triad scores and anxiety levels, frequently returning to baseline. Furthermore, self-esteem, which is commonly diminished in individuals experiencing chronic pain, tends to improve upon pain resolution.

The phenomenon of catastrophizing has been proposed as a significant factor in the subjective experience of pain. Pain catastrophizing encompasses a propensity to articulate pain experiences with greater exaggeration than typical individuals, to ruminate extensively on pain sensations when they manifest, or to perceive a heightened sense of helplessness regarding the experience. Individuals who achieve elevated scores on catastrophization assessments typically report a more intense pain experience compared to those with lower scores. A common inference is that the inclination to catastrophize causes an individual to perceive pain with increased intensity. One hypothesis suggests that catastrophizing modulates pain perception by modifying attentional focus, influencing anticipation, and amplifying emotional reactions to pain. Nevertheless, certain facets of catastrophization might represent the product of severe pain rather than its antecedent. Specifically, a more intense pain sensation may predispose an individual to thoughts consistent with the definition of catastrophization.

Co-occurrence with Trauma

A substantial comorbidity exists between post-traumatic stress disorder (PTSD) and chronic pain. Patients diagnosed with both PTSD and chronic pain consistently report greater pain severity compared to individuals without co-occurring PTSD.

Co-occurrence with Depression

Individuals experiencing chronic pain frequently exhibit depressive symptoms. A 2017 report by the British Medical Association indicated that 49% of chronic pain sufferers also presented with depression.

Cognitive Impact

The cognitive effects of chronic pain represent an area requiring further investigation, though preliminary findings have emerged. A majority of individuals afflicted with chronic pain report cognitive deficits, including memory lapses, attentional difficulties, and challenges in task completion. Objective assessments have revealed that chronic pain patients often exhibit impairments in attention, memory, cognitive flexibility, verbal fluency, response speed during cognitive tasks, and efficiency in structured task execution. A comprehensive review of studies conducted in 2018 identified a correlation between chronic pain and atypical performance on tests evaluating memory, attention, and processing speed.

Societal and Personal Ramifications

Social Support Mechanisms

Social support significantly influences outcomes for individuals experiencing chronic pain. Specifically, varying levels and forms of social support have been linked to alterations in pain intensity, pain management, and resilience to pain. Extensive research in this domain has primarily examined emotional, instrumental, tangible, and informational social support. Individuals with persistent pain conditions frequently utilize social support as a coping strategy, demonstrating improved outcomes when integrated into broader, more supportive social networks. A substantial body of research indicates a direct and significant correlation between social engagement or social support and pain perception. Elevated pain levels were consistently associated with diminished social activities, reduced social support, and impaired social functioning.

Racial Discrepancies

Unconscious biases and negative stereotyping against racial minority patients seeking pain treatment have been documented, though a 2017 review suggested these biases did not impact clinical decision-making. Minority individuals may face denial of pain diagnoses and medication, undergo more frequent substance abuse assessments, and are less likely to be referred to pain specialists. A 2010 study by University of Michigan Health revealed that Black patients in pain clinics received only 50% of the medication dosage administered to White patients. Initial investigations also indicated that healthcare providers might exhibit reduced empathy for Black patients and underestimate their pain severity, leading to delayed treatment. Furthermore, language barriers can impede effective communication and engagement between minority patients and healthcare providers during pain management.

Perceptions of Inequity

Similar to the detrimental impacts associated with catastrophizing, the perception of injustice is considered a factor in exacerbating both the intensity and persistence of chronic pain. This pain-related perception of injustice is defined as a cognitive appraisal encompassing the profound and irreversible nature of losses stemming from pain or injury (e.g., expressing a desire to 'regain my life'), alongside the attribution of blame and unfairness to external sources (e.g., stating 'I am suffering due to someone else's negligence'). Consequently, addressing issues related to top-down processing and cognitive appraisals has been proposed as a strategy to enhance the comprehension and management of this condition.

Chronic Pain and the Impact of COVID-19

The COVID-19 pandemic significantly disrupted numerous lives, resulting in substantial physical, psychological, and socioeconomic repercussions across the general populace. Social distancing measures, implemented as a response to the pandemic, fundamentally altered established patterns of social interaction, thereby fostering an environment that some psychologists characterized as a period of collective grief.

Amidst a substantial segment of the global population experiencing extended durations of social isolation and psychological distress, a particular study revealed that individuals afflicted with chronic pain reported heightened empathy for their suffering throughout the pandemic.

The Relationship Between Chronic Pain and Conventional Medical Practices

Individuals experiencing chronic pain frequently occupy an ambiguous status, occasionally articulating that their specific form of suffering positions them both within and beyond the purview of conventional medical paradigms.

The Impact of Chronic Pain in Professional Environments

Within professional settings, chronic pain conditions represent a substantial challenge for both affected individuals and their employing organizations; this issue is projected to intensify in numerous nations due to an aging labor force. Consequently, organizations might benefit from evaluating the social dynamics of their workplaces and assessing how these dynamics could either alleviate or exacerbate chronic pain challenges for employees. For instance, some research indicates that elevated levels of socially prescribed perfectionism (perfectionism stemming from external pressures, such as those from a supervisor) can interact with feelings of guilt experienced by individuals with chronic pain, leading to increased job-related tension and diminished job satisfaction.

A 2025 Swedish cohort study, involving more than 10,000 patients undergoing treatment for high-impact chronic pain, revealed that approximately one-quarter experienced sickness absence exceeding 180 days within a three-year period. This investigation identified prior sickness absence as the most significant predictor of subsequent long-term absence, followed by co-occurring neurological disorders, reduced self-assessed work capacity and recovery confidence, female gender, extended pain duration, and household income.

• List of chronic pain syndromes
• Dopaminergic pathways
• Neurodegeneration
• Neurotherapy

Notes

References

Dowell D, Haegerich TM, Chou R (April 2016). "CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016". JAMA. 315 (15): 1624–1645. doi:10.1001/jama.2016.1464. PMC 6390846. PMID 26977696.

• Dowell D, Haegerich TM, Chou R (April 2016). "CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016". JAMA. 315 (15): 1624–1645. doi:10.1001/jama.2016.1464. PMC 6390846. PMID 26977696.Kahn, Jennifer (2025-01-12). "Chronic Pain Is a Hidden Epidemic. It's Time for a Revolution". The New York Times. Retrieved 2025-02-27.
  • International Association for the Study of Pain Archived 2021-05-01 at the Wayback Machine
  • Media related to pain at Wikimedia Commons